Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01772719 · OUTCOME

Incidence Rate of Toxicity

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid · Source last updated 2019-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Every 12 months up to one month after treatment completion

What was measured

Descriptive statistics will be provided regarding incidence rates of toxicity. Patients will be monitored for safety throughout the study.

Analysis population: Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study

Groups in this outcome

Simvastatin and Zoledronic Acid

Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2\. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Simvastatin and Zoledronic Acid0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Descriptive statistics will be provided regarding incidence rates of toxicity. Patients will be monitored for safety throughout the study.
groups
  1. description
    Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2\. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
    id
    OG000
    title
    Simvastatin and Zoledronic Acid
population Description
Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study
reporting Status
POSTED
time Frame
Every 12 months up to one month after treatment completion
title
Incidence Rate of Toxicity
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice